Marine Natural Products and Other Derivatives as Potent Indoleamine 2,3-Dioxygenase Inhibitors

被引：16

作者：

Delfourne, Evelyne ^{[1
]}

机构：

[1] Univ Paul Sabatier, UMR CNRS 5068, Lab Synth & Physicochim Mol Interet Biol, F-31062 Toulouse 9, France

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2012年 / 12卷 / 10期

关键词：

Indoleamine 2,3-dioxygenase; IDO inhibitors; marine natural compounds; COMPETITIVE INHIBITORS; IMMUNE ESCAPE; EXIGUAMINE-A; TRYPTOPHAN; BINDING; TARGET; IDO; MECHANISM; CANCER;

D O I：

10.2174/138955712802762374

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Cancer cells are able to elaborate enzymatic mechanisms allowing tumors to resist or escape imune rejection. Among the enzymes involved, indoleamine 2,3-dioxygenase (IDO), an intracellular enzyme that initiates the first and rate-limiting step of tryptophan breakdown along the kynurenine pathway, has emerged as a promising molecular target for the development of new immunotherapeutic anticancer agents. This review summarizes the synthesis and IDO activities of the different classes of marine and other inhibitors reported so far.

引用

页码：988 / 996

页数：9

共 50 条

[41] Indoleamine 2,3-dioxygenase, Tregs and Cancer
Munn, D. H.
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (15) : 2240 - 2246
[42] Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening
Guo, Wei
Yao, Sheng
Sun, Pu
Yang, Tian-biao
Tang, Chun-ping
Zheng, Ming-yue
Ye, Yang
Meng, Ling-hua
ACTA PHARMACOLOGICA SINICA, 2020, 41 (03) : 423 - 431
[43] Indoleamine 2,3-Dioxygenase Is It an Immune Suppressor?
Soliman, Hatem
Mediavilla-Varela, Melanie
Antonia, Scott
CANCER JOURNAL, 2010, 16 (04) : 354 - 359
[44] Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1)
Fung, Sai-Parng S.
Wang, Haiyan
Tomek, Petr
Squire, Christopher J.
Flanagan, Jack U.
Palmer, Brian D.
Bridewell, David J. A.
Tijono, Sofian M.
Jamie, Joanne F.
Ching, Lai-Ming
BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (24) : 7595 - 7603
[45] Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors
Dolusic, Eduard
Larrieu, Pierre
Blanc, Sebastien
Sapunaric, Frederic
Pouyez, Jenny
Moineaux, Laurence
Colette, Delphine
Stroobant, Vincent
Pilotte, Luc
Colau, Didier
Ferain, Thierry
Fraser, Graeme
Galleni, Moreno
Frere, Jean-Marie
Masereel, Bernard
Van den Eynde, Benoit
Wouters, Johan
Frederick, Raphael
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2011, 46 (07) : 3058 - 3065
[46] Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
Balog, Aaron
Lin, Tai-An
Maley, Derrick
Gullo-Brown, Johnni
Kandoussi, Enzo Hamza
Zeng, Jianing
Hunt, John T.
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (03) : 467 - 476
[47] Posttranslational modification of indoleamine 2,3-dioxygenase
Fujigaki, Hidetsugu
Seishima, Mitsuru
Saito, Kuniaki
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2012, 403 (07) : 1777 - 1782
[48] Posttranslational modification of indoleamine 2,3-dioxygenase
Hidetsugu Fujigaki
Mitsuru Seishima
Kuniaki Saito
Analytical and Bioanalytical Chemistry, 2012, 403 : 1777 - 1782
[49] Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase
Rafice, Sara A.
Chauhan, Nishma
Efimov, Igor
Basran, Jaswir
Raven, Emma Lloyd
BIOCHEMICAL SOCIETY TRANSACTIONS, 2009, 37 : 408 - 412
[50] Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
Prendergast, G. C.
Chang, M. Y.
Mandik-Nayak, L.
Metz, R.
Muller, A. J.
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (15) : 2257 - 2262

← 1 2 3 4 5 →